Search Results - "Bradley, John D"

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis by Fleischmann, Roy, Kremer, Joel, Cush, John, Schulze-Koops, Hendrik, Connell, Carol A, Bradley, John D, Gruben, David, Wallenstein, Gene V, Zwillich, Samuel H, Kanik, Keith S

“…In a placebo-controlled trial, monotherapy with tofacitinib, an oral Janus kinase inhibitor, reduced the symptoms and signs of rheumatoid arthritis. Adverse…”
Get full text

Tofacitinib versus Methotrexate in Rheumatoid Arthritis by Lee, Eun Bong, Fleischmann, Roy, Hall, Stephen, Wilkinson, Bethanie, Bradley, John D, Gruben, David, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene V, Zang, Chuanbo, Zwillich, Samuel H, van Vollenhoven, Ronald F

“…In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and…”
Get full text

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis by van Vollenhoven, Ronald F, Fleischmann, Roy, Cohen, Stanley, Lee, Eun Bong, García Meijide, Juan A, Wagner, Sylke, Forejtova, Sarka, Zwillich, Samuel H, Gruben, David, Koncz, Tamas, Wallenstein, Gene V, Krishnaswami, Sriram, Bradley, John D, Wilkinson, Bethanie

“…In this trial of patients with rheumatoid arthritis who were on stable doses of methotrexate, tofacitinib, a novel oral Janus kinase inhibitor, was more…”
Get full text

Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials by Landewé, Robert B M, Connell, Carol A, Bradley, John D, Wilkinson, Bethanie, Gruben, David, Strengholt, Sander, van der Heijde, Désirée

“…The detection of statistically significant reductions in radiographic progression during clinical studies in patients with rheumatoid arthritis (RA) has become…”
Get full text

Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study by van der Heijde, Désirée, Tanaka, Yoshiya, Fleischmann, Roy, Keystone, Edward, Kremer, Joel, Zerbini, Cristiano, Cardiel, Mario H., Cohen, Stanley, Nash, Peter, Song, Yeong‐Wook, Tegzová, Dana, Wyman, Bradley T., Gruben, David, Benda, Birgitta, Wallenstein, Gene, Krishnaswami, Sriram, Zwillich, Samuel H., Bradley, John D., Connell, Carol A.

“…Objective The purpose of this 24‐month phase III study was to examine structural preservation with tofacitinib in patients with rheumatoid arthritis (RA) with…”
Get full text

Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques by Conaghan, Philip G, Østergaard, Mikkel, Bowes, Michael A, Wu, Chunying, Fuerst, Thomas, van der Heijde, Désirée, Irazoque-Palazuelos, Fedra, Soto-Raices, Oscar, Hrycaj, Pawel, Xie, Zhiyong, Zhang, Richard, Wyman, Bradley T, Bradley, John D, Soma, Koshika, Wilkinson, Bethanie

“…To explore the effects of tofacitinib-an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA)-with or without methotrexate (MTX), on MRI…”
Get more information

Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study by McInnes, Iain B, Kim, Ho-Youn, Lee, Sang-Heon, Mandel, David, Song, Yeong-Wook, Connell, Carol A, Luo, Zhen, Brosnan, M Julia, Zuckerman, Andrea, Zwillich, Samuel H, Bradley, John D

“…To evaluate the efficacy and safety of atorvastatin versus placebo in modifying lipids in patients with rheumatoid arthritis (RA) receiving the oral Janus…”
Get more information

Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT by Sawitzke, Allen D, Shi, Helen, Finco, Martha F, Dunlop, Dorothy D, Harris, Crystal L, Singer, Nora G, Bradley, John D, Silver, David, Jackson, Christopher G, Lane, Nancy E, Oddis, Chester V, Wolfe, Fred, Lisse, Jeffrey, Furst, Daniel E, Bingham, Clifton O, Reda, Domenic J, Moskowitz, Roland W, Williams, H James, Clegg, Daniel O

“…Knee osteoarthritis (OA) is a major cause of pain and functional limitation in older adults, yet longer-term studies of medical treatment of OA are limited. To…”
Get more information

Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis by Clegg, Daniel O, Reda, Domenic J, Harris, Crystal L, Klein, Marguerite A, O'Dell, James R, Hooper, Michele M, Bradley, John D, Bingham, Clifton O, Weisman, Michael H, Jackson, Christopher G, Lane, Nancy E, Cush, John J, Moreland, Larry W, Schumacher, H. Ralph, Oddis, Chester V, Wolfe, Frederick, Molitor, Jerry A, Yocum, David E, Schnitzer, Thomas J, Furst, Daniel E, Sawitzke, Allen D, Shi, Helen, Brandt, Kenneth D, Moskowitz, Roland W, Williams, H. James

“…In this 24-week trial, glucosamine and chondroitin sulfate were not more effective, alone or in combination, than placebo in controlling pain in patients with…”
Get full text

Severity of joint pain and Kellgren-Lawrence grade at baseline are better predictors of joint space narrowing than bone scintigraphy in obese women with knee osteoarthritis by MAZZUCA, Steven A, BRANDT, Kenneth D, HECK, Louis W, YOCUM, David E, SCHNITZER, Thomas J, SHARMA, Leena, MANZI, Susan, ODDIS, Chester V, SCHAUWECKER, Donald S, KATZ, Barry P, MEYER, Joan M, LANE, Kathleen A, BRADLEY, John D, HUGENBERG, Steven T, WOLFE, Frederick, MORELAND, Larry W

“…OBJECTIVE: To compare the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of a baseline late-phase bone scan and…”
Get full text

Conjugacy Classes in Sylow p-Subgroups of Finite Chevalley Groups in Bad Characteristic by Bradley, John D., Goodwin, Simon M.

“…Let U = U(q) be a Sylow p-subgroup of a finite Chevalley group G = G(q). Röhrle and Goodwin in 2009 determined a parameterization of the conjugacy classes of…”
Get full text

Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis by Jansen, Jeroen P, Vieira, Maria-Cecilia, Bradley, John D, Cappelleri, Joseph C, Zwillich, Samuel H, Wallenstein, Gene V

“…Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and joint structural deterioration. Driven by recent expectations that…”
Get full text

Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis by Wells, Alvin F., Greenwald, Maria, Bradley, John D., Alam, Jahangir, Arora, Vipin, Kartman, Cynthia E.

“…Introduction This article evaluates the efficacy and safety of baricitinib 4 mg versus placebo in United States including Puerto Rico (US) and rest of the…”
Get full text

The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: A report from the glucosamine/chondroitin arthritis intervention trial by Sawitzke, Allen D., Shi, Helen, Finco, Martha F., Dunlop, Dorothy D., Bingham, Clifton O., Harris, Crystal L., Singer, Nora G., Bradley, John D., Silver, David, Jackson, Christopher G., Lane, Nancy E., Oddis, Chester V., Wolfe, Fred, Lisse, Jeffrey, Furst, Daniel E., Reda, Domenic J., Moskowitz, Roland W., Williams, H. James, Clegg, Daniel O.

“…Objective Osteoarthritis (OA) of the knee causes significant morbidity and current medical treatment is limited to symptom relief, while therapies able to slow…”
Get full text

Comparison of an Antiinflammatory Dose of Ibuprofen, an Analgesic Dose of Ibuprofen, and Acetaminophen in the Treatment of Patients with Osteoarthritis of the Knee by Bradley, John D, Brandt, Kenneth D, Katz, Barry P, Kalasinski, Lorrie A, Ryan, Sarah I

“…OSTEOARTHRITIS is the most common joint disease; as much as 80 percent of the population has radiographic evidence of osteoarthritis by the age of 65. 1…”
Get full text

Joint irrigation as treatment for osteoarthritis by Bradley, John D

“…Irrigation is necessary to achieve distension and visualization of the joint during arthroscopy. Clinical improvement observed after diagnostic arthroscopy has…”
Get full text

In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs by Yu, Guo-Liang, Bradley, John D, Attardi, Laura D, Blackburn, Elizabeth H

“…Mutating the CAACCCCAA sequence in the RNA component of telomerase causes the synthesis in vivo of new telomere sequences corresponding to the mutated RNA…”
Get full text

Tolerance to the Therapeutic Effect of Tadalafil Does Not Occur During 6 Months of Treatment: A Randomized, Double‐Blind, Placebo‐Controlled Study in Men with Erectile Dysfunction by McMahon, Chris G., Carson, Culley C., Fischer, Christopher J., Wang, Wei Christine, Florio, Vincent A., Bradley, John D.

“…Tolerance can cause a decrease in drug efficacy during chronic therapy, possibly leading to treatment failures. The aim of this article is to determine whether…”
Get full text

A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis by BRADLEY, John D, DMITRIENKO, Alexei A, KIVITZ, Alan J, GLUCK, Oscar S, WEAVER, Arthur L, WIESENHUTTER, Craig, MYERS, Stephen L, SIDES, Gregory D

“…OBJECTIVE: To evaluate the efficacy and safety of a selective inhibitor of secretory phospholipase (sPLA2), LY333013, in the treatment of rheumatoid arthritis…”
Get full text

Effects of doxycycline on progression of osteoarthritis: Results of a randomized, placebo‐controlled, double‐blind trial by Brandt, Kenneth D., Mazzuca, Steven A., Katz, Barry P., Lane, Kathleen A., Buckwalter, Kenneth A., Yocum, David E., Wolfe, Frederick, Schnitzer, Thomas J., Moreland, Larry W., Manzi, Susan, Bradley, John D., Sharma, Leena, Oddis, Chester V., Hugenberg, Steven T., Heck, Louis W.

“…Objective To confirm preclinical data suggesting that doxycycline can slow the progression of osteoarthritis (OA). The primary outcome measure was joint space…”
Get full text